Abstract-Bcl-2 family proteins can be classified into two subfamilies-anti-apoptotic members and pro-apoptotic members. Mechanistically, these two subfamilies can antagonize each other through heterodimerization while homodimerization has been proposed for each subfamily to carry out their corresponding anti-apoptotic or pro-apoptotic functions. To date, many small-molecule antagonists against anti-apoptotic Bcl-2 proteins have been developed, which are monomeric modulators. In this study, a series of BH3I-1 based dimeric modulators were developed with structure-activity relationship explored. Dimeric modulators compared to the monomeric antagonists have enhanced binding activity against anti-apoptotic Bcl-2 proteins. In addition, the acidic functional group was demonstrated to be critical for the binding interaction of the small-molecule antagonists with anti-apoptotic Bcl-2 proteins. Finally, the representative dimeric modulator revealed enhanced activity in inducing cytochrome c release from mitochondria compared to its monomeric counterpart. Taken together, dimerization of monomeric modulators is one practical approach to enhance the bioactivity of Bcl-2 antagonists.
Drug resistance is a major challenge in cancer chemotherapy. 1 The over-expression of anti-apoptotic Bcl-2 proteins which protects cells from apoptosis is one mechanism for tumors to acquire drug resistance. [2] [3] [4] Inhibiting anti-apoptotic Bcl-2 proteins, therefore, is one promising strategy to nullify drug resistance in cancer treatment, which has been proved valid through anti-sense approach. 5 Mechanistically, anti-apoptotic Bcl-2 proteins protect cells from apoptosis by antagonizing pro-apoptotic Bcl-2 proteins through dimerization. 6, 7 Structural studies of a complex of Bcl-X L protein and a pro-apoptotic peptide (Bak BH3) have revealed a hydrophobic cleft on Bcl-X L protein as the binding pocket for the pro-apoptotic peptide 8 and molecules binding to that hydrophobic cleft may overcome the protective effect of the Bcl-X L protein. 9 These observations have stimulated the recent discovery of small molecule based antagonists-a few of which are currently at various stages of clinical evaluation, such as gossypol, apogossypol, TW-37, and ABT-737. [10] [11] [12] [13] [14] As Bcl-2 proteins form homo/hetero oligomers for their physiological functions, multivalent modulators may potentially possess unique functions that are not present in the monomeric modulators. 15 In addition, it is well established that multivalency of ligands could enhance potency compared to the monomeric ones. 16, 17 To test these concepts in the Bcl-2 protein family, we developed a series of dimeric analogs of 3e based on BH3I-1, a small-molecule Bcl-2 antagonist developed by Degterev et al. 18 Several dimeric modulators demonstrated enhanced potency to inhibit the binding of a BH3-domain Bak peptide binding to the anti-apoptotic Bcl-2 proteins while dimerization through the carboxylic acid group on 3e resulted in substantial loss of the activity. Further SAR studies confirmed that the carboxylic acid was critical for the antagonism of the small molecule against the Bcl-2 proteins. The enhanced potency of the dimeric modulators was further confirmed by its ability to induce cytochrome c release from isolated mitochondria. The cytochrome c release study also suggested that the dimeric modulator functionally mimics the monomeric antagonist.
The preparation of the dimeric modulators (3e-D1-D4) followed the general synthetic route outlined in Scheme 1 (The preparation of the dimeric modulators 3e-D5-D7 followed a similar synthetic route detailed in Supplementary Materials.). 19 Briefly, the syntheses of 3e-D1-D4 started with L L-phenylalanine, which first reacted with carbon disulfide and cyclized upon chloroacetate treatment to form the rhodanine compound in 45% yield. The rhodanine compound (2.2 equivalent) was then condensed with various dimeric aldehydes in refluxing toluene to afford compound 3e-D1-D4 in 76-92% yield. These four dimeric analogs were evaluated in the antiapoptotic Bcl-2 protein binding assays. 19 The binding was assessed for their activity to prevent the binding of Bak peptide binding to anti-apoptotic Bcl-2, Bcl-X L , and Bcl-w. All of the four dimeric modulators demonstrated improved potency to prevent the binding of Bak peptide to the three anti-apoptotic Bcl-2 proteins tested ( Table 1) . The best candidate, 3e-D2, demonstrated 5-to 16-fold increase of potency compared to the monomeric 3e. The optimal linker between the monomers is a four-atom ethylene glycolic liner-increase or decrease of linker length would result in decreased activity.
Delighted by these results, we further explored the other dimerization of the monomeric 3e. 3e-D5-D7 were prepared by using L L-phenylalanine based rhodanine, which first reacted with various ethylene glycol to form the dimeric rhodanines in 34-81% yield (Supplementary Materials). The dimeric rhodanines were then condensed with 5-bromobenzaldehyde (2.2 equivalent) for 3e-D5-D7 (82-95%). These three dimers, however, all demonstrated substantial decrease of potency to prevent Bak peptide binding to anti-apoptotic Bcl-2 proteins (Table 1) . One potential cause for the loss of activity would be due to the mask of the carboxylic acid functional group on 3e. To test this hypothesis, we synthesized 3e ethyl ester and 3e ethyl ester dimer by following the same procedure for the preparation of Bak peptide binding to the anti-apoptotic Bcl-2 proteins relative to 3e (>5-fold loss) and 3e-1D (>15-fold loss), respectively. 3e Ethyl ester dimer still revealed better potency than the monomeric 3e ethyl ester. These SAR studies demonstrate the carboxylic acid functional group on 3e is critical for its interaction with anti-apoptotic Bcl-2 proteins. In fact, quite a few of the reported small-molecule antagonists against anti-apoptotic Bcl-2 proteins have acidic functional groups, such as gossypol, apogossypol, ABT-737, TW-37, and the recent flavonoid compound developed by Wang et al. (The acidic protons are highlighted in Fig. 1.) Wang et al. also observed that masking the acidic functional group resulted in dramatic loss of the activity against anti-apoptotic Bcl-2 proteins. 20, 21 Our study herein, in combination with the other studies, suggests that an acidic functional group may be optimal for small-molecule antagonists against anti-apoptotic Bcl-2 proteins (Fig. 2) .
To explore whether the monomeric modulator and dimeric modulator may function differently, we evaluated 3e and 3e-D2 for their ability to induce cytochrome c release from mitochondria, a key feature for mitochondrial-mediated apoptotic cascade. Both candidates induced cytochrome c release from the isolated mitochondria (Fig. 3) . The respective concentration to induce 50% cytochrome c release for 3e was about 69 lM while that for 3e-D2 was $6 lM, correlating with their potency to antagonize the anti-apoptotic Bcl-2 proteins. However, further investigations are required to unambiguously identify the target of the compounds on mitochondria.
In summary, dimerization of monomeric antagonist 3e could enhance the potency to bind the anti-apoptotic Bcl-2 proteins. The dimeric modulator also had enhanced activity to induce cytochrome c release from mitochondria. These studies demonstrated that the dimerization is an effective approach to enhance the potency of Bcl-2 antagonists. In addition, our SAR studies in combination with others suggest that an acidic functional group is critical for the antagonism of the small molecules against anti-apoptotic Bcl-2 proteins. Our current studies also suggest that the dimeric modulators have the same function as the monomeric antagonists.
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bottom flask equipped with a magnetic stirrer, L L-phenylalanine (1 mmol) was dissolved with sodium hydroxide (80 mg, 2 mmol) in water (10 ml). Then, carbon disulfide (60 ll, 1 mmol) was added to the reaction mixture, which was stirred vigorously overnight. An aqueous solution of ClCH 2 CO 2 Na (1 ml, 1 M, 1 mmol) was added and stirring was continued at 23°C for 3 h. Then hydrochloric acid solution (3 ml, 5.5 N, 16.5 mmol) was added and the reaction mixture was refluxed overnight. The reaction mixture was neutralized with saturated NaHCO 3 solution. The solvent was removed under vacuum and the cyclized product was purified by flash chromatography. In a round-bottom flask equipped with a reflux condenser and a magnetic stirrer, cyclized rhodanine intermediate (1 mmol) , and Bcl-w were prepared. To determine the binding affinity of small molecules for an anti-apoptotic Bcl-2 protein, a series of 3-fold dilutions of small molecules were prepared in dimethylsulfoxide, that is, 10 mM, 3.33 mM, 1.11 mM, 0.37 mM, 0.123 mM, 0.041 mM, 0.014 mM, and 0 mM. To each well in a 96-well half-area black plate, 5 ll of the small molecule stock solution was added. A solution containing 50 nM Flu-Bak peptide and the anti-apoptotic Bcl-2 protein to be tested in PBS buffer, pH 7.0, 1 mM DTT was prepared and incubated at 23°C for one hour. The concentration of the anti-apoptotic Bcl-2 protein used corresponds to the one that resulted in 60% of Flu-Bak peptide complex with the anti-apoptotic Bcl-2 protein and such a concentration was determined in the Flu-Bak and Bcl-2 protein saturation binding experiment. The corresponding concentrations of Bcl-2, Bcl-X L , and Bcl-w needed to achieve 60% complex formation under the assay conditions are 1000 nM, 880 nM, and 1200 nM, respectively. To each well the Flu-Bak peptide and antiapoptotic Bcl-2 protein solution (45 ll) was added by auto-injection at a rate of 200 ll/s. The sample was incubated at 23°C for one hour and shaken for two seconds before fluorescence polarization (in mP unit) was measured. Controls included dose-response measurements in the absence of proteins to assess for any interactions between the compounds and the Flu-Bak peptide. Eventual effects were taken into account by subtraction. The inhibitory constant (K i ) was determined by fitting the FP changes to the concentration of the small molecule competing ligand by using an equation developed in Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. Anal. Biochem. 2004, 332, 261. For cytochrome c release, mitochondria were isolated from mouse liver using differential centrifugation for
